The EMA has recommended updating Comirnaty 10 mg formulations, including JN.1, KP.2, and LP.8.1 versions, to allow COVID-19 vaccination in individuals aged 6 months or older.

Despite a plan to jack up the price of Comirnaty to between $110 and $130 per dose when the United States goes to a commercial model this year for COVID-19 vaccines, Pfizer expects revenue from the ...

An advisory committee to the US Food and Drug Administration (FDA) voted 16-2 on Friday against approval of a third booster dose added on to the 2-dose regimen for Pfizer’s COVID-19 vaccine Comirnaty.

The Comirnaty 2025-2026 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, a descendant of JN.1. The Food and Drug Administration (FDA) has approved Comirnaty ® (LP.8.1-adapted monovalent ...

AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net ...

Following suit with other companies that produce COVID-19 vaccines, BioNTech has discovered demand for its Pfizer-partnered, omicron-adapted shot has not met expectations this fall and has had to ...

Valneva’s plans to establish its COVID-19 vaccine as a booster to Pfizer and BioNTech’s Comirnaty have taken a blow, with a clinical trial of the shot eliciting “only a marginally increased ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...

(RTTNews) - Pfizer Canada ULC and BioNTech SE (BNTX) announced that Health Canada has authorized the LP.8.1 variant adapted COMIRNATY COVID-19 vaccine for individuals aged 6 months and older. The ...

An international research team comprised of members from the School of Public Health, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), the Laboratory of Data Discovery for Health (D24H ...